Stay informed with the latest litigation news. Explore now

IP Verse

Astrazeneca Ab competitive analysis

Latest publications and patents of Astrazeneca Ab New

Explore the latest publications and patents granted to Astrazeneca Ab, showcasing their recent innovations and technological advancements.

Last updated on: Sep 3, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Astrazeneca Ab

EP3045466
Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of DiabetesPatent Maintained As Amended
EP4114465
Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous InjectionGranted And Under Opposition
EP2508188
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol HydrateGranted And Under Opposition
EP3769781
Apr 19, 2023Stable Anti-Ifnar1 FormulationGranted And Under Opposition
EP2785349
Nov 9, 2022Combination Treatment Of CancerPatent Maintained As Amended
EP3142661
Oct 6, 2021Method For Suppressing Glucagon Secretion Of An Sglt2 InhibitorRevoked
EP2139494
Mar 11, 2020Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol HydrateGranted And Under Opposition
EP3363807
Nov 13, 2019Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol SolvateGranted And Under Opposition
EP2498759
Aug 1, 2018Immediate Release Tablet FormulationsGranted And Under Opposition
EP2498758
Jul 25, 2018Bilayer Tablet FormulationsGranted And Under Opposition

Latest patents of Astrazeneca Ab opposed by its competitors

Explore Astrazeneca Ab's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 4, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3045466
Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes1
EP4114465
Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous Injection1
EP2508188
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
EP3769781
Apr 19, 2023Stable Anti-Ifnar1 Formulation1
EP2785349
Nov 9, 2022Combination Treatment Of Cancer1
EP3142661
Oct 6, 2021Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor1
EP2139494
Mar 11, 2020Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate6
EP3363807
Nov 13, 2019Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate1
EP2498759
Aug 1, 2018Immediate Release Tablet Formulations4
EP2498758
Jul 25, 2018Bilayer Tablet Formulations1

Latest PTAB cases involving Astrazeneca Ab New

Discover the latest PTAB cases involving Astrazeneca Ab, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 9, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Astrazeneca Ab

IPR2017-01913Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-01912Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-01910Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-00905Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00904Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00900Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00631Jan 9, 2017COMPLEX INNOVATIONSASTRAZENECA ABInstitution Denied
IPR2016-01326Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABTerminated-Settled
IPR2016-01325Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABInstitution Denied
IPR2016-01324Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABTerminated-Settled

Top competitors of Astrazeneca Ab

Top competitors of Astrazeneca Ab based on patent oppositions.